SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Oravax(orvx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: LTK007 who wrote (113)4/23/1999 6:45:00 PM
From: Ploni  Read Replies (1) of 127
 
Max,

I received my proxy today, and it looks as though we'll be getting 85 cents a share of Peptide stock for each share of Oravax stock.

That's about what I had expected, and I continue to be surprised that ORVX is selling around 50 cents. It still looks like a lot of free money lying around to me.

The only surprise was that it sounds as though the only outlet for Peptide stock will be on the London exchange. I had thought there was discussion about retaining the OTC (or reclaiming the NASD) listing for Peptide ADR's, so they'd be represented on the US markets.

- Charles
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News